dr-sabine-mueller-md-48051-1440x784-2x
dr-sabine-mueller-md-48051-320x320-2x

Sabine Mueller

MD PhD

Pediatric neurologist
Pediatric neuro-oncologist

Dr. Sabine Mueller is a pediatric neuro-oncologist who specializes in caring for children with brain tumors and related genetic syndromes. Before completing medical school, she worked as a scientist, director of genomics and project leader for a brain tumor program at AGY Therapeutics, a biotechnology company in South San Francisco.

In her research, Mueller studies treatments for children with brain tumors, looking especially at improving long-term cognitive outcomes.

Mueller earned her medical degree at the Universität Hamburg Faculty of Medicine and earned a doctorate in biochemistry and molecular biology in collaboration with AGY. After a residency in pediatrics at Massachusetts General Hospital, she completed a fellowship in pediatric oncology at UCSF.

  • Education

    Universität Hamburg School of Medicine, MD, 2005

  • Residencies

    Massachusetts General Hospital, Pediatrics, 2006

  • Fellowships

    UCSF Medical Center, Pediatric Oncology, 2009

Clinics I work with

(3)

neurofibromatosis-type-1-nf1-clinic-320x320-2x

Neurofibromatosis Type 1 (NF1) Clinic

Neurofibromatosis Type 1 (NF1) Clinic

1825 Fourth St., Fifth Floor, 5A
San Francisco, CA 94158

oncology-clinic-320x320-2x 3

Oncology Clinic

Oncology Clinic

San Francisco / Oakland / Walnut Creek

3

Brain Tumor Program

Brain Tumor Program

San Francisco / Oakland / Walnut Creek

Decorative Caduceus

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...

Events occurring on or after treatment on Day 1 will be summarized by mapped term, appropriate thesaurus level, and CTCAE v5.0 grade. Adverse events leading to treatment discontinuation will be listed.

Recruiting

More about this study
Decorative Caduceus

Fimepinostat in Treating Brain Tumors in Children and Young Adults

Will be analyzed using descriptive statistics from results of fimepinostat concentrations measured within the tumor tissue collected at the time of a standard of care surgery or biopsy. Within each strata, Simon's two-stage design...

Recruiting

More about this study
Decorative Caduceus

Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurren...

Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments in all 3 treatment groups compared to archived recurrent pediatric HGG group. The number of participants with ...

Recruiting

More about this study
Decorative Caduceus

TAK-580 In Gliomas and Other Tumors

A DLT is defined as an AE assessed as at least possibly related to the study medication, which occurs during Cycle 1 (typically 28 days following the first dose of TAK-580)

Recruiting

More about this study
Decorative Caduceus

Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurren...

We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...

Recruiting

More about this study
Decorative Caduceus

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Glioma...

Safety of the vaccine (Strata A and B) or vaccine in combination with nivolumab (Stratum C) will be assessed by monitoring for adverse events (AEs), scheduled laboratory assessments, vital signs, & physical examinations for subjec...

Recruiting

More about this study
Decorative Caduceus

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or...

The safety of the modified measles virus will be assessed by monitoring for adverse events. Subjects will be monitored for adverse events via scheduled laboratory assessments, vital sign measurements, and physical examinations. Th...

Recruiting

More about this study
Decorative Caduceus

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrins...

Safety of repeated CED of nal-IRI following standard of care focal radiotherapy will be assessed by monitoring for adverse events, scheduled laboratory assessments, vital sign measurements, and physical examinations for subjects w...

Recruiting

More about this study
See all clinical trials

Smell the roses

Wander outside into our Butterfly Garden in Oakland and our healing gardens at Mission Bay.

Share